Business
Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio
--News Direct--Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to announce the acquisition of Healion Bio, including its entire
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"--News Direct--Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to announce the acquisition of Healion Bio, including its entire portfolio of next-generation antiviral technology assets. Lederman said the acquired portfolio of infectious disease assets includes a class of potential broad-spectrum antiviral agents, TNX-3900, with a host-directed mechanism. Tonix said it plans to develop the TNX-3900 series of molecules as oral antivirals, either as monotherapy or in combination with other antivirals. Contact DetailsProactive USA+1 [email protected] source version on newsdirect.com: https://newsdirect.com/news/tonix-pharmaceuticals-announces-acquisition-of-healion-bio-antiviral-portfolio-399030216","length":1314,"tagName":"div"}]